Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biweekly TAS-102 with Bevacizumab combination study

Trial Profile

Biweekly TAS-102 with Bevacizumab combination study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BiTS study
  • Most Recent Events

    • 14 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top